References
- Wenkui L , ZhangJ, TseFLS. Handbook of LC–MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations. John Wiley & Sons Inc., Hoboken, NJ, USA (2013).
- US FDA . Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) (2001). www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.
- Korfmacher W . High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures. Bioanalysis3 (11), 1169–1171 (2011).
- Zhang NR , YuS, TillerP, YehS, MahanE, EmaryWB. Quantitation of small molecules using high-resolution accurate mass spectrometers – a different approach for analysis of biological samples. Rapid Commun. Mass Spectrom. 23 (7), 1085–1094 (2009).
- Kaufmann A , ButcherP, MadenK, WalkerS, WidmerM. Quantitative and confirmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25 (7), 979–992 (2011).
- Xian F , HendricksonC, MarshallA. High resolution mass spectrometry. Anal. Chem. 84 (2), 708–719 (2012).
- Matuszewski B , ConstanzerM, Chavez-EngC. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 70 (5), 882–889 (1998).
- Chambers E , Wagrowski-DiehlD, LuZ, MazzeoJ. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B852, 22–34 (2007).
- Kellie JF , KehlerJR, SzapacsME. Application of high-resolution MS for development of peptide and large-molecule drug candidates. Bioanalysis8 (3), 169–177 (2016).
- Ramakrishnan P , NairS, RangiaK. A method for comparative metabolomics in urine using high resolution mass spectrometry. J. Chromatogr. A1443, 83–92 (2016).
- Gertsman I , GangoitiJ, BarshopB. Validation of a dual LC-HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics. Metabolomics10 (2), 312–323 (2014).
- Xu K , LiuL, SaadOMet al. Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry. Anal. Biochem. 412, 56–66 (2011).
- Dorywalska M , StropP, Melton-WittJAet al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug. Chem. 26 (4), 650–665 (2015).
- Bowen C , KehlerJ, BoramS, AbberleyL, SzapacsM, EvansC. Modify on the fly: triple quad to high resolution in support of a dermal clinical study requiring an ultra-low LLOQ. Bioanalysis8 (3), 205–214 (2016).
- Evans C . HR-MS for small molecule regulatory submission. Presented at : 10th Workshop on Recent Issues in Bioanalysis. Orlando, FL, USA, 18–22 April 2016.